ADC Therapeutics SA Profit Loss Before Tax
ADC Therapeutics SA (ADCT) reported Profit Loss Before Tax of -$47.89 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes
ifrs-full:ProfitLossBeforeTax · last filed 2023-11-07
- ADC Therapeutics SA profit loss before tax for the quarter ending 2023-09-30 was -$47.89M.
- ADC Therapeutics SA profit loss before tax for the quarter ending 2023-06-30 was -$53.73M.
- ADC Therapeutics SA profit loss before tax for the quarter ending 2023-03-31 was -$59.69M.
- ADC Therapeutics SA profit loss before tax for the quarter ending 2022-12-31 was -$20.19M.
| Period end | Profit Loss Before Tax 3 month | Profit Loss Before Tax 6 month | Profit Loss Before Tax 9 month | Profit Loss Before Tax 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$47.89M 6-K · filed 2023-11-07 | -$101.62M derived: sum of 2 quarters · filed 2023-11-07 | -$161.31M 6-K · filed 2023-11-07 | -$181.50M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | -$53.73M 6-K · filed 2023-08-08 | -$113.42M 6-K · filed 2023-08-08 | -$133.60M derived: sum of 3 quarters · filed 2023-08-08 | -$184.92M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | -$59.69M 6-K · filed 2023-05-09 | -$79.88M derived: sum of 2 quarters · filed 2023-05-09 | -$131.20M derived: sum of 3 quarters · filed 2023-11-07 | -$196.52M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | -$20.19M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$71.51M derived: sum of 2 quarters · filed 2023-11-07 | -$136.83M derived: sum of 3 quarters · filed 2023-11-07 | -$154.66M 20-F · filed 2023-03-15 |
| 2022-09-30 | -$51.32M 6-K · filed 2023-11-07 | -$116.64M derived: sum of 2 quarters · filed 2023-11-07 | -$134.47M 6-K · filed 2023-11-07 | -$190.82M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$65.32M 6-K · filed 2023-08-08 | -$83.15M 6-K · filed 2023-08-08 | -$139.50M derived: sum of 3 quarters · filed 2023-08-08 | -$210.91M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$17.83M 6-K · filed 2023-05-09 | -$74.18M derived: sum of 2 quarters · filed 2023-05-09 | -$145.59M derived: sum of 3 quarters · filed 2023-05-09 | -$217.92M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$56.35M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$127.76M derived: sum of 2 quarters · filed 2023-03-15 | -$200.09M derived: sum of 3 quarters · filed 2023-03-15 | -$251.50M 20-F · filed 2023-03-15 |
| 2021-09-30 | -$71.40M 6-K · filed 2022-11-08 | -$143.73M derived: sum of 2 quarters · filed 2022-11-08 | -$195.15M 6-K · filed 2022-11-08 | -$250.96M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$72.33M 6-K · filed 2022-08-09 | -$123.75M 6-K · filed 2022-08-09 | -$179.55M derived: sum of 3 quarters · filed 2023-03-15 | -$199.88M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$51.42M 6-K · filed 2022-05-09 | -$107.22M derived: sum of 2 quarters · filed 2023-03-15 | -$127.55M derived: sum of 3 quarters · filed 2023-03-15 | -$254.01M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$55.80M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$76.13M derived: sum of 2 quarters · filed 2023-03-15 | -$202.59M derived: sum of 3 quarters · filed 2023-03-15 | -$245.96M 20-F · filed 2023-03-15 |
| 2020-09-30 | -$20.33M 6-K · filed 2021-11-02 | -$146.78M derived: sum of 2 quarters · filed 2021-11-02 | -$190.16M 6-K · filed 2021-11-02 | |
| 2020-06-30 | -$126.45M 6-K · filed 2021-08-03 | -$169.83M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | -$43.38M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | -$115.90M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | -$122.87M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |